SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Artemis Therapeutics, Inc. – ‘10-Q’ for 3/31/20 – ‘EX-101.CAL’

On:  Thursday, 5/14/20, at 12:14pm ET   ·   For:  3/31/20   ·   Accession #:  1178913-20-1480   ·   File #:  0-24431

Previous ‘10-Q’:  ‘10-Q’ on 11/14/19 for 9/30/19   ·   Next:  ‘10-Q’ on 8/12/20 for 6/30/20   ·   Latest:  ‘10-Q’ on 11/21/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/14/20  Artemis Therapeutics, Inc.        10-Q        3/31/20   42:2M                                     Z-K Global Ltd/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    236K 
 2: EX-31.1     Certification -- §302 - SOA'02 -- exhibit_31-1      HTML     19K 
 3: EX-32.1     Certification -- §906 - SOA'02 -- exhibit_32-1      HTML     15K 
13: R1          Document and Entity Information                     HTML     51K 
33: R2          Interim Condensed Consolidated Balance Sheets       HTML     80K 
38: R3          Interim Condensed Consolidated Balance Sheets       HTML     36K 
                (Parenthetical)                                                  
26: R4          Interim Condensed Consolidated Statements of        HTML     43K 
                Comprehensive (Loss) (Unaudited)                                 
14: R5          Interim Condensed Statements of Stockholders'       HTML     40K 
                Equity (Unaudited)                                               
34: R6          Interim Condensed Consolidated Statement of Cash    HTML     45K 
                Flows (Unaudited)                                                
39: R7          General                                             HTML     27K 
25: R8          Significant Accounting Policies                     HTML     37K 
16: R9          Commitments and Contingencies                       HTML     19K 
12: R10         Income Tax                                          HTML     45K 
22: R11         Warrants Issued to Investors                        HTML     22K 
36: R12         Computation of Net Loss per Share                   HTML     35K 
32: R13         Stock Capital                                       HTML     74K 
11: R14         Related Parties                                     HTML     19K 
21: R15         Subsequent Events                                   HTML     17K 
35: R16         Significant Accounting Policies (Policies)          HTML     65K 
31: R17         Income Tax (Tables)                                 HTML     41K 
10: R18         Warrants Issued to Investors (Tables)               HTML     23K 
23: R19         Computation of Net Loss per Share (Tables)          HTML     33K 
41: R20         Stock Capital (Tables)                              HTML     66K 
29: R21         Commitments and Contingencies (Details)             HTML     19K 
18: R22         Income Tax (Narrative) (Details)                    HTML     20K 
20: R23         Income Tax (Schedule of Deferred Income Taxes)      HTML     21K 
                (Details)                                                        
40: R24         Income Tax (Schedule of Net Operating Loss          HTML     19K 
                Carryforwards) (Details)                                         
28: R25         Warrants Issued to Investors (Details)              HTML     20K 
17: R26         Computation of Net Loss per Share (Schedule of      HTML     40K 
                Calculation of Basic Loss Per Share) (Details)                   
19: R27         Stock Capital (Narrative) (Details)                 HTML     49K 
42: R28         Stock Capital (Summary of Stock Option Activity)    HTML     50K 
                (Details)                                                        
27: R29         Stock Capital (Summary of Stock Option Exercise     HTML     35K 
                price) (Details)                                                 
30: R30         Related Parties (Narrative) (Details)               HTML     25K 
37: XML         IDEA XML File -- Filing Summary                      XML     71K 
15: EXCEL       IDEA Workbook of Financial Reports                  XLSX     34K 
 4: EX-101.INS  XBRL Instance -- atms-20200331                       XML    592K 
 6: EX-101.CAL  XBRL Calculations -- atms-20200331_cal               XML     66K 
 7: EX-101.DEF  XBRL Definitions -- atms-20200331_def                XML    185K 
 8: EX-101.LAB  XBRL Labels -- atms-20200331_lab                     XML    403K 
 9: EX-101.PRE  XBRL Presentations -- atms-20200331_pre              XML    300K 
 5: EX-101.SCH  XBRL Schema -- atms-20200331                         XSD     83K 
24: ZIP         XBRL Zipped Folder -- 0001178913-20-001480-xbrl      Zip     56K 


‘EX-101.CAL’   —   XBRL Calculations — atms-20200331_cal


This Exhibit is an XBRL XML File.


                                                                                                                                                                                
<?xml version="1.0" standalone="no" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3a -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
<!-- Field: Doc-Info; Name: Source; Value: ATMS 0320 10Q.xfr; Date: 2020%2D05%2D14T14:24:16Z -->
<!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://artemistherapeutics.com/role/inks-daei" xlink:href="atms-20200331.xsd#inks-daei" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/inks-ccbs" xlink:href="atms-20200331.xsd#inks-ccbs" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/inks-ccbsp" xlink:href="atms-20200331.xsd#inks-ccbsp" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/inks-ccsoo" xlink:href="atms-20200331.xsd#inks-ccsoo" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/InterimCondensedStatementsOfStockholdersEquity" xlink:href="atms-20200331.xsd#InterimCondensedStatementsOfStockholdersEquity" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:href="atms-20200331.xsd#InterimCondensedConsolidatedStatementOfCashFlows" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/inks-bop" xlink:href="atms-20200331.xsd#inks-bop" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/SignificantAccountingPolicies" xlink:href="atms-20200331.xsd#SignificantAccountingPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/CommitmentsAndContingencies" xlink:href="atms-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/IncomeTax" xlink:href="atms-20200331.xsd#IncomeTax" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/WarrantsIssuedToInvestors" xlink:href="atms-20200331.xsd#WarrantsIssuedToInvestors" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/ComputationOfNetLossPerShare" xlink:href="atms-20200331.xsd#ComputationOfNetLossPerShare" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/StockCapital" xlink:href="atms-20200331.xsd#StockCapital" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/RelatedParties" xlink:href="atms-20200331.xsd#RelatedParties" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/SubsequentEvents" xlink:href="atms-20200331.xsd#SubsequentEvents" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="atms-20200331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/IncomeTaxTables" xlink:href="atms-20200331.xsd#IncomeTaxTables" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/WarrantsIssuedToInvestorsTables" xlink:href="atms-20200331.xsd#WarrantsIssuedToInvestorsTables" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/ComputationOfNetLossPerShareTables" xlink:href="atms-20200331.xsd#ComputationOfNetLossPerShareTables" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/StockCapitalTables" xlink:href="atms-20200331.xsd#StockCapitalTables" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:href="atms-20200331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/IncomeTaxNarrativeDetails" xlink:href="atms-20200331.xsd#IncomeTaxNarrativeDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/IncomeTaxScheduleOfDeferredIncomeTaxesDetails" xlink:href="atms-20200331.xsd#IncomeTaxScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/IncomeTaxScheduleOfNetOperatingLossCarryforwardsDetails" xlink:href="atms-20200331.xsd#IncomeTaxScheduleOfNetOperatingLossCarryforwardsDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/WarrantsIssuedToInvestorsDetails" xlink:href="atms-20200331.xsd#WarrantsIssuedToInvestorsDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/ComputationOfNetLossPerShareScheduleOfCalculationOfBasicLossPerShareDetails" xlink:href="atms-20200331.xsd#ComputationOfNetLossPerShareScheduleOfCalculationOfBasicLossPerShareDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/StockCapitalNarrativeDetails" xlink:href="atms-20200331.xsd#StockCapitalNarrativeDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/StockCapitalSummaryOfStockOptionActivityDetails" xlink:href="atms-20200331.xsd#StockCapitalSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/StockCapitalSummaryOfStockOptionExercisePriceDetails" xlink:href="atms-20200331.xsd#StockCapitalSummaryOfStockOptionExercisePriceDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://artemistherapeutics.com/role/RelatedPartiesNarrativeDetails" xlink:href="atms-20200331.xsd#RelatedPartiesNarrativeDetails" xlink:type="simple"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/inks-daei" xlink:title="00000001 - Document - Document and Entity Information"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/inks-ccbs" xlink:title="00000002 - Statement - Interim Condensed Consolidated Balance Sheets">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesNoncurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDueToRelatedPartiesNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/inks-ccbsp" xlink:title="00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Parenthetical)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/inks-ccsoo" xlink:title="00000004 - Statement - Interim Condensed Consolidated Statements of Comprehensive (Loss) (Unaudited)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/InterimCondensedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Interim Condensed Statements of Stockholders&apos; Equity (Unaudited)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/InterimCondensedConsolidatedStatementOfCashFlows" xlink:title="00000006 - Statement - Interim Condensed Consolidated Statement of Cash Flows (Unaudited)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="atms-20200331.xsd#atms_IncreaseDecreaseInOtherAccountsReceivablesAndPrepaidExpenses" xlink:label="loc_atmsIncreaseDecreaseInOtherAccountsReceivablesAndPrepaidExpenses"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atmsIncreaseDecreaseInOtherAccountsReceivablesAndPrepaidExpenses" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/inks-bop" xlink:title="00000007 - Disclosure - GENERAL"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - COMMITMENTS AND CONTINGENCIES"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/IncomeTax" xlink:title="00000010 - Disclosure - INCOME TAX"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/WarrantsIssuedToInvestors" xlink:title="00000011 - Disclosure - WARRANTS ISSUED TO INVESTORS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/ComputationOfNetLossPerShare" xlink:title="00000012 - Disclosure - Computation of Net Loss per Share"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/StockCapital" xlink:title="00000013 - Disclosure - STOCK CAPITAL"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/RelatedParties" xlink:title="00000014 - Disclosure - RELATED PARTIES"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/SubsequentEvents" xlink:title="00000015 - Disclosure - SUBSEQUENT EVENTS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/IncomeTaxTables" xlink:title="00000017 - Disclosure - INCOME TAX (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/WarrantsIssuedToInvestorsTables" xlink:title="00000018 - Disclosure - WARRANTS ISSUED TO INVESTORS (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/ComputationOfNetLossPerShareTables" xlink:title="00000019 - Disclosure - Computation of Net Loss per Share (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/StockCapitalTables" xlink:title="00000020 - Disclosure - STOCK CAPITAL (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/IncomeTaxNarrativeDetails" xlink:title="00000022 - Disclosure - INCOME TAX (Narrative) (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/IncomeTaxScheduleOfDeferredIncomeTaxesDetails" xlink:title="00000023 - Disclosure - INCOME TAX (Schedule of Deferred Income Taxes) (Details)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/IncomeTaxScheduleOfNetOperatingLossCarryforwardsDetails" xlink:title="00000024 - Disclosure - INCOME TAX (Schedule of Net Operating Loss Carryforwards) (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/WarrantsIssuedToInvestorsDetails" xlink:title="00000025 - Disclosure - WARRANTS ISSUED TO INVESTORS (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/ComputationOfNetLossPerShareScheduleOfCalculationOfBasicLossPerShareDetails" xlink:title="00000026 - Disclosure - Computation of Net Loss per Share (Schedule of Calculation of Basic Loss Per Share) (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/StockCapitalNarrativeDetails" xlink:title="00000027 - Disclosure - STOCK CAPITAL (Narrative) (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/StockCapitalSummaryOfStockOptionActivityDetails" xlink:title="00000028 - Disclosure - STOCK CAPITAL (Summary of Stock Option Activity) (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/StockCapitalSummaryOfStockOptionExercisePriceDetails" xlink:title="00000029 - Disclosure - STOCK CAPITAL (Summary of Stock Option Exercise price) (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://artemistherapeutics.com/role/RelatedPartiesNarrativeDetails" xlink:title="00000030 - Disclosure - RELATED PARTIES (Narrative) (Details)"/>
</link:linkbase>

Top
Filing Submission 0001178913-20-001480   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 11:18:00.1pm ET